

Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone

Authors

Ricardo D. Parrondo,^{1*} Ricardo de Menezes,^{1,2*} Hanna Sledge,³ Madhavi Nayyar,¹ Kanika Yadav,¹ Leif Bergsagel,⁴ Rafael Fonseca,⁴ Prashant Kapoor,⁵ Francis Buadi,⁵ Morie A. Gertz,⁵ Angela Dispenzieri,⁵ Vivek Roy,¹ Taimur Sher,¹ Moritz Binder,⁵ Nadine Abdallah,⁵ Saurabh Chhabra,⁴ S. Vincent Rajkumar,⁵ Wilson I. Gonsalves,⁵ Joselle Cook,⁵ David Dingli,⁵ Yi Lin,⁵ Andre Fernandez,¹ Caitlin Flott,¹ Udit Yadav,⁴ Rahma M. Warsame,⁵ Erin E. Wiedmeier-Nutor,⁴ Taxiarchis Kourelis,⁵ Nelson Leung,⁵ Mustaqeem A. Siddiqui,⁵ Shaji Kumar,⁵ Asher A. Chanan-Khan¹ and Sikander Ailawadhi¹

¹Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL USA; ²Department of Hematology, Hospital Moinhos de Vento, Porto Alegre, Brazil; ³Division of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA; ⁴Division of Hematology-Oncology,

Mayo Clinic, Phoenix, AZ, USA and ⁵Division of Hematology, Mayo Clinic, Rochester, MN, USA

**RDP and RdM contributed equally as first authors.*

Correspondence:
R.D. PARRONDO - Parrondo.Ricardo@mayo.edu

<https://doi.org/10.3324/haematol.2025.300401>

Received: December 21, 2025.
Accepted: February 23, 2026.
Early view: March 5, 2026.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

Supplemental Table 1. Patient Characteristics (N=464)	
Age, Median (range)	64.0 (26.0, 86.0)
Gender, n (%)	
Male	278 (59.9%)
Female	186 (40.1%)
Race, n (%)	
White	406 (87.7%)
Black	23 (5.0%)
Ethnicity, n (%)	
Hispanic	15 (3.2%)
Not Hispanic or Latino	438 (94.4%)
Not reported	11 (2.4%)
Myeloma Isotype, n (%)	
IgG Kappa	177 (38.1%)
IgG Lambda	77 (16.6%)
IgA Kappa	69 (14.9%)
IgA Lambda	42 (9.1%)
Kappa Light Chain	59 (12.7%)
Lambda Light Chain	21 (4.5%)
Non-Secretory	8 (1.7%)
Other	11 (2.4%)
ISS Stage, n (%)	
I	92 (19.8%)
II	151 (32.5%)
III	114 (24.6%)
N/A	107 (23.1%)
R-ISS Stage, n (%)	
I	98 (21.1%)
II	80 (17.2%)

III	205 (44.2%)
N/A	81 (17.5%)
Risk Stratification, n (%)	
Standard	182 (40.2%)
High	106 (23.4%)
Ultra High Risk	165 (36.4%)
FISH abnormalities, n (%)	
t(11;14)	66 (15.2%)
Del17p	80 (18.4%)
t(4;14)	55 (12.7%)
t(14;16)	19 (4.4%)
t(14;20)	8 (1.8%)
1q gain or amplification	193 (44.5%)
Deletion 1p	13 (3.0%)
Renal Insufficiency* at Diagnosis, n (%)	
No	417 (89.9%)
Yes	47 (10.1%)
Extramedullary Disease, n (%)	
No	384 (82.8%)
Yes	80 (17.2%)
Underwent Autologous Transplant, n%)	
No	149 (32.1%)
Yes	315 (67.9%)
*Renal insufficiency defined as creatinine >2 mg/dL and/or creatinine clearance <40 mL/min	